None.
None.
Holdings compared (excluding cash instruments): 37 → 37.
| Holding | from | to |
|---|---|---|
| Roche Holding Ltd | 18.01% | 17.00% |
| Novartis AG | 15.30% | 16.02% |
| Holding | 5 Aug | 31 Aug |
|---|---|---|
| Roche Holding Ltd | 17.19% | 16.31% |
| Novartis AG | 15.38% | 16.02% |
| AstraZeneca PLC | 13.11% | 13.28% |
| Novo Nordisk A/S Class B | 7.93% | 7.97% |
| GSK plc | 5.75% | 5.56% |
| Sanofi SA | 5.08% | 5.28% |
| argenx SE | 2.92% | 3.49% |
| Bayer AG | 3.05% | 3.02% |
| EssilorLuxottica SA | 3.23% | 2.91% |
| Lonza Group AG | 2.67% | 2.71% |
Combined top-10 weight: 76.3% → 76.5%.
Bars scaled to the change: orange = up, grey = down. Basket percentages at the two snapshots.
| Country | 5 Aug | 31 Aug |
|---|---|---|
| Belgium | 4.9% | 5.4% |
| Switzerland | 43.5% | 43.1% |
| Denmark | 9.5% | 9.7% |
The three countries that moved the most between the two snapshots.
−1% in EUR (NAV 229.89 → 227.55, 31 Jul → 31 Aug). Accumulating fund: no distributions.
588 mln € → 576 mln € (issuer’s daily series).
| TER | 0.18% — unchanged |
| Transaction costs (KID) | 0.02% — unchanged |
| Index, name, policy | no change in the period |